Status and phase
Conditions
Treatments
About
The goal of this clinical trial is to evaluate the effectiveness and safety of hyperthermic intraperitoneal chemotherapy combined with intravenous chemotherapy in peritoneal metastatic pancreatic cancer. The main question it aims to answer are:
(1) Does this combined approach increase 1-year survival rates? and (2) What is the safety profile of this treatment regimen?
Participants will:
undergo baseline imaging and surgical exploration to confirm peritoneal metastasis, receive two cycles of intraperitoneal cisplatin HIPEC (70mg/m²) postoperatively, followed by systemic AG chemotherapy (nab-paclitaxel plus gemcitabine), with treatment adjustments based on regular imaging assessments and multidisciplinary team (MDT) recommendations.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
90 participants in 1 patient group
Loading...
Central trial contact
Wenquan Wang, Dr
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal